Aristotelis Bamias, MD, discusses key efficacy data from a final analysis of the phase 3 IMvigor130 trial in metastatic urothelial carcinoma.
Aristotelis Bamias, MD
Advertisement
Articles by Aristotelis Bamias, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5